Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 69

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Mutant TP53 Posttranslational Modifications: Challenges and Opportunities

Nguyen, Thuy-Ai, Menendez, Daniel, Resnick, Michael A., Anderson, Carl W.·2014·Human Mutation
DOI 10.1002/humu.22506
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/humu.22506

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 150

  1. Acs, 2011, The AAA-ATPase VCP/p97 promotes 53BP1 recruitment by removing L3MBTL1 from DNA double-strand breaks, Nat Struct Mol Biol, 18, 1345, 10.1038/nsmb.2188 · DOI · Paper page
  2. Adorno, 2009, A mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasis, Cell, 137, 87, 10.1016/j.cell.2009.01.039 · DOI · Paper page
  3. Anderson, 2009, Handbook of cell signaling, 2185
  4. Armata, 2007, The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression, Cancer Res, 67, 11696, 10.1158/0008-5472.CAN-07-1610 · DOI
  5. Armata, 2010, Requirement of the ATM/p53 tumor suppressor pathway for glucose homeostasis, Mol Cell Biol, 30, 5787, 10.1128/MCB.00347-10 · DOI
  6. Bar, 2009, Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors, Int J Gynecol Cancer, 19, 1322, 10.1111/IGC.0b013e3181b70465 · DOI
  7. Bartkova, 2007, DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours, Oncogene, 26, 7414, 10.1038/sj.onc.1210553 · DOI
  8. Bech-Otschir, 2001, COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system, EMBO J, 20, 1630, 10.1093/emboj/20.7.1630 · DOI · Paper page
  9. Bensimon, 2011, Beyond ATM: the protein kinase landscape of the DNA damage response, FEBS Lett, 585, 1625, 10.1016/j.febslet.2011.05.013 · DOI · Paper page
  10. Berger, 2005, Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage, Mol Cell Biol, 25, 5380, 10.1128/MCB.25.13.5380-5388.2005 · DOI
  11. Brooks, 2003, Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation, Curr Opin Cell Biol, 15, 164, 10.1016/S0955-0674(03)00003-6 · DOI · Paper page
  12. Burns, 2003, Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells, Mol Cell Biol, 23, 5556, 10.1128/MCB.23.16.5556-5571.2003 · DOI · Paper page
  13. Campaner, 2011, The methyltransferase Set7/9 (Setd7) is dispensable for the p53-mediated DNA damage response in vivo, Mol Cell, 43, 681, 10.1016/j.molcel.2011.08.007 · DOI
  14. Carr, 2012, Lysine methylation and the regulation of p53, Essays Biochem, 52, 79, 10.1042/bse0520079 · DOI
  15. Carter, 2009, Modifications of p53: competing for the lysines, Curr Opin Genet Dev, 19, 18, 10.1016/j.gde.2008.11.010 · DOI
  16. Chao, 2006a, Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression, EMBO J, 25, 2615
  17. Chao, 2006b, Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage, Mol Cell Biol, 26, 6859, 10.1128/MCB.00062-06 · DOI
  18. Coffill, 2012, Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion, EMBO Rep, 13, 638, 10.1038/embor.2012.74 · DOI
  19. Collavin, 2010, p53-family proteins and their regulators: hubs and spokes in tumor suppression, Cell Death Differ, 17, 901, 10.1038/cdd.2010.35 · DOI · Paper page
  20. Cordenonsi, 2007, Integration of TGF-β and Ras/MAPK signaling through p53 phosphorylation, Science, 315, 840, 10.1126/science.1135961 · DOI · Paper page
  21. Cui, 2012, PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53, Nat Struct Mol Biol, 19, 916, 10.1038/nsmb.2353 · DOI
  22. Dai, 2010, p53 post-translational modification: deregulated in tumorigenesis, Trends Mol Med, 16, 528, 10.1016/j.molmed.2010.09.002 · DOI · Paper page
  23. Dai, 2013, Negative regulation of the acetyltransferase TIP60-p53 interplay by UHRF1 (ubiquitin-like with PHD and RING Finger Domains 1), J Biol Chem, 288, 19581, 10.1074/jbc.M113.476606 · DOI
  24. Dai, 2011, Differential effects on p53-mediated cell cycle arrest vs. apoptosis by p90, Proc Natl Acad Sci U S A, 108, 18937, 10.1073/pnas.1110988108 · DOI
  25. Debnath, 2011, Peptide-protein interactions suggest that acetylation of lysines 381 and 382 of p53 is important for positive coactivator 4-p53 interaction, J Biol Chem, 286, 25076, 10.1074/jbc.M110.205328 · doi:10.1074/jbc.m110.205328
  26. Donehower, 2014, Insights into wildtype and mutant p53 functions provided by genetically engineered mice, Hum Mutat, 35, 715, 10.1002/humu.22507 · DOI
  27. Donehower, 2009, 20 years studying p53 functions in genetically engineered mice, Nat Rev Cancer, 9, 831, 10.1038/nrc2731 · DOI · Paper page
  28. Elston, 2012, Crosstalk between p53 and TGF-β signalling, J Signal Transduct, 2012, 294097, 10.1155/2012/294097 · DOI
  29. Emamzadah, 2011, Crystal structure of a multidomain human p53 tetramer bound to the natural CDKN1A (p21) p53-response element, Mol Cancer Res, 9, 1493, 10.1158/1541-7786.MCR-11-0351 · DOI
  30. Endicott, 2012, The structural basis for control of eukaryotic protein kinases, Annu Rev Biochem, 81, 587, 10.1146/annurev-biochem-052410-090317 · DOI · Paper page
  31. Feng, 2006, Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence, Cell Cycle, 5, 2812, 10.4161/cc.5.23.3526 · DOI
  32. Ferreon, 2009, Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2, Proc Natl Acad Sci USA, 106, 6591, 10.1073/pnas.0811023106 · DOI · Paper page
  33. Freeman, 2013, The impact of post-transcriptional regulation in the p53 network, Brief Funct Genomics, 12, 46, 10.1093/bfgp/els058 · DOI
  34. Furihata, 2002, Frequent phosphorylation at serine 392 in overexpressed p53 protein due to missense mutation in carcinoma of the urinary tract, J Pathol, 197, 82, 10.1002/path.1082 · DOI
  35. Gardino, 2011, 14-3-3 proteins as signaling integration points for cell cycle control and apoptosis, Semin Cell Dev Biol, 22, 688, 10.1016/j.semcdb.2011.09.008 · DOI · Paper page
  36. Gillotin, 2010, Mutation at Ser392 specifically sensitizes mutant p53H175 to mdm2-mediated degradation, Cell Cycle, 9, 1390, 10.4161/cc.9.7.11253 · DOI
  37. Girardini, 2011, A Pin1/mutant p53 axis promotes aggressiveness in breast cancer, Cancer Cell, 20, 79, 10.1016/j.ccr.2011.06.004 · DOI · Paper page
  38. Goh, 2011, The role of mutant p53 in human cancer, J Pathol, 223, 116, 10.1002/path.2784 · DOI · Paper page
  39. Gu, 2012, Surf the post-translational modification network of p53 regulation, Int J Biol Sci, 8, 672, 10.7150/ijbs.4283 · DOI · Paper page
  40. Haupt, 2009, Promyelocytic leukemia protein is required for gain of function by mutant p53, Cancer Res, 69, 4818, 10.1158/0008-5472.CAN-08-4010 · DOI
  41. Hock, 2010, Regulation of the p53 pathway by ubiquitin and related proteins, Int J Biochem Cell Biol, 42, 1618, 10.1016/j.biocel.2010.06.011 · DOI
  42. Hollstein, 1991, p53 mutations in human cancers, Science, 253, 49, 10.1126/science.1905840 · DOI · Paper page
  43. Hoogervorst, 2005, Lack of p53 Ser389 phosphorylation predisposes mice to develop 2-acetylaminofluorene-induced bladder tumors but not ionizing radiation-induced lymphomas, Cancer Res, 65, 3610, 10.1158/0008-5472.CAN-04-4328 · DOI
  44. Huang, 2007, p53 is regulated by the lysine demethylase LSD1, Nature, 449, 105, 10.1038/nature06092 · DOI · Paper page
  45. Huang, 2012, Global tumor protein p53/p63 interactome: making a case for cisplatin chemoresistance, Cell Cycle, 11, 2367, 10.4161/cc.20863 · DOI
  46. Hupp, 1995, Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner, J Biol Chem, 270, 18165, 10.1074/jbc.270.30.18165 · DOI
  47. Iwabuchi, 1994, Two cellular proteins that bind to wild-type but not mutant p53, Proc Natl Acad Sci USA, 91, 6098, 10.1073/pnas.91.13.6098 · DOI · Paper page
  48. Jansson, 2008, Arginine methylation regulates the p53 response, Nat Cell Biol, 10, 1431, 10.1038/ncb1802 · DOI · Paper page
  49. Jeffrey, 1995, Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms, Science, 267, 1498, 10.1126/science.7878469 · DOI · Paper page
  50. Jenkins, 2012, p53 N-terminal phosphorylation: a defining layer of complex regulation, Carcinogenesis, 33, 1441, 10.1093/carcin/bgs145 · DOI
  51. Jenkins, 2008, Quantitative proteomics analysis of the effects of ionizing radiation in wild type and p53K317R knock-in mouse thymocytes, Mol Cell Proteomics, 7, 716, 10.1074/mcp.M700482-MCP200 · DOI
  52. Jiang, 2011, Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages, Proc Natl Acad Sci USA, 108, 17123, 10.1073/pnas.1111245108 · DOI
  53. Kachirskaia, 2008, Role for 53BP1 tudor domain recognition of p53 dimethylated at lysine 382 in DNA damage signaling, J Biol Chem, 283, 34660, 10.1074/jbc.M806020200 · DOI
  54. Kamada, 2011, Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation, J Biol Chem, 286, 252, 10.1074/jbc.M110.174698 · DOI
  55. Kato, 2003, Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis, Proc Natl Acad Sci USA, 100, 8424, 10.1073/pnas.1431692100 · DOI · Paper page
  56. Keller, 2001, A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1, Mol Cell, 7, 283, 10.1016/S1097-2765(01)00176-9 · DOI · Paper page
  57. Kim, 2012, Functional interplay between p53 acetylation and H1.2 phosphorylation in p53-regulated transcription, Oncogene, 31, 4290, 10.1038/onc.2011.605 · DOI
  58. Krummel, 2005, The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation, Proc Natl Acad Sci USA, 102, 10188, 10.1073/pnas.0503068102 · DOI · Paper page
  59. Kruse, 2009a, MSL2 promotes Mdm2-independent cytoplasmic localization of p53, J Biol Chem, 284, 3250, 10.1074/jbc.M805658200 · DOI
  60. Kulikov, 2006, Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation, J Biol Chem, 281, 28575, 10.1074/jbc.M513311200 · DOI
  61. Kurash, 2008, Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo, Mol Cell, 29, 392, 10.1016/j.molcel.2007.12.025 · DOI · Paper page
  62. Kurimchak, 2013, PP2A counterbalances phosphorylation of pRB and mitotic proteins by multiple CDKs: potential implications for PP2A disruption in cancer, Genes Cancer, 3, 739, 10.1177/1947601912473479 · DOI
  63. Lane, 2010, Mdm2 and p53 are highly conserved from placozoans to man, Cell Cycle, 9, 540, 10.4161/cc.9.3.10516 · DOI
  64. Lang, 2004, Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome, Cell, 119, 861, 10.1016/j.cell.2004.11.006 · DOI · Paper page
  65. Latronico, 2001, An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors, J Clin Endocrinol Metab, 86, 4970, 10.1210/jcem.86.10.7957 · DOI · Paper page
  66. Lee, 2010, Graded enhancement of p53 binding to CREB-binding protein (CBP) by multisite phosphorylation, Proc Natl Acad Sci USA, 107, 19290, 10.1073/pnas.1013078107 · DOI · Paper page
  67. Lee, 2012, Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo, Cancer Cell, 22, 751, 10.1016/j.ccr.2012.10.022 · DOI
  68. Lee, 2011, Serine 312 phosphorylation is dispensable for wild-type p53 functions in vivo, Cell Death Differ, 18, 214, 10.1038/cdd.2010.90 · DOI
  69. Lehnertz, 2011, p53-dependent transcription and tumor suppression are not affected in Set7/9-deficient mice, Mol Cell, 43, 673, 10.1016/j.molcel.2011.08.006 · DOI
  70. Leroy, 2013, The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis, Nucleic Acids Res, 41, D962, 10.1093/nar/gks1033 · DOI · Paper page
  71. Li, 2007, An acetylation switch in p53 mediates holo-TFIID recruitment, Mol Cell, 28, 408, 10.1016/j.molcel.2007.09.006 · DOI
  72. Li, 2011, Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells, Mol Cancer Res, 9, 577, 10.1158/1541-7786.MCR-10-0534 · DOI · Paper page
  73. Li, 2012, Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence, Cell, 149, 1269, 10.1016/j.cell.2012.04.026 · DOI · Paper page
  74. Li, 2013, PKB-mediated PHF20 phosphorylation on Ser291 is required for p53 function in DNA damage, Cell Signal, 25, 74, 10.1016/j.cellsig.2012.09.009 · DOI
  75. Lin, 2005, p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression, Nat Cell Biol, 7, 165, 10.1038/ncb1211 · DOI · Paper page
  76. Liou, 2011, Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins, Trends Biochem Sci, 36, 501, 10.1016/j.tibs.2011.07.001 · DOI · Paper page
  77. Liu, 2013, Functional p53 determines docetaxel sensitivity in prostate cancer cells, Prostate, 73, 418, 10.1002/pros.22583 · DOI
  78. Liu, 2004, Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215, J Biol Chem, 279, 52175, 10.1074/jbc.M406802200 · DOI · Paper page
  79. Loughery, 2013, Switching on p53: an essential role for protein phosphorylation, BioDiscovery, 8, 1
  80. Lozano, 2007, The oncogenic roles of p53 mutants in mouse models, Curr Opin Genet Dev, 17, 66, 10.1016/j.gde.2006.12.003 · DOI
  81. Lu, 2008, The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways, Cancer Metastasis Rev, 27, 123, 10.1007/s10555-008-9127-x · DOI · Paper page
  82. MacLaine, 2009, The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway, Aging (Albany NY), 1, 490, 10.18632/aging.100047 · DOI
  83. Maki, 1999, Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2, J Biol Chem, 274, 16531, 10.1074/jbc.274.23.16531 · DOI
  84. Mantovani, 2007, The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP, Nat Struct Mol Biol, 14, 912, 10.1038/nsmb1306 · DOI
  85. Matsumoto, 2004a, Phosphorylation state of tumor-suppressor gene p53 product overexpressed in skin tumors, Oncol Rep, 12, 1039
  86. Matsumoto, 2004b, Prognostic significance of serine 392 phosphorylation in overexpressed p53 protein in human esophageal squamous cell carcinoma, Oncology, 67, 143, 10.1159/000081001 · DOI
  87. Matsumoto, 2006, Posttranslational phosphorylation of mutant p53 protein in tumor development, Med Mol Morphol, 39, 79, 10.1007/s00795-006-0320-0 · DOI
  88. Meek, 2009, Tumour suppression by p53: a role for the DNA damage response, Nat Rev Cancer, 9, 714, 10.1038/nrc2716 · DOI · Paper page
  89. Meek, 2009, Posttranslational modification of p53: cooperative integrators of function, Cold Spring Harb Perspect Biol, 1, a000950, 10.1101/cshperspect.a000950 · DOI · Paper page
  90. Mellert, 2007, The ARF/oncogene pathway activates p53 acetylation within the DNA binding domain, Cell Cycle, 6, 1304, 10.4161/cc.6.11.4343 · DOI
  91. Melnikova, 2003, Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase, Oncogene, 22, 5958, 10.1038/sj.onc.1206595 · DOI
  92. Midgley, 1997, p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding, Oncogene, 15, 1179, 10.1038/sj.onc.1201459 · DOI · Paper page
  93. Minamoto, 2001, Distinct pattern of p53 phosphorylation in human tumors, Oncogene, 20, 3341, 10.1038/sj.onc.1204458 · DOI
  94. Muller, 2011, p53 and its mutants in tumor cell migration and invasion, J Cell Biol, 192, 209, 10.1083/jcb.201009059 · DOI · Paper page
  95. Muller, 2013, p53 mutations in cancer, Nat Cell Biol, 15, 2, 10.1038/ncb2641 · DOI · Paper page
  96. Nagata, 1999, The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association, Oncogene, 18, 6037, 10.1038/sj.onc.1202978 · DOI
  97. Noon, 2011, 53BP1-mediated DNA double strand break repair: insert bad pun here, DNA Repair (Amst), 10, 1071, 10.1016/j.dnarep.2011.07.012 · DOI
  98. Odell, 2013, A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation, J Biol Chem, 288, 16704, 10.1074/jbc.M112.443168 · DOI · Paper page
  99. Okaichi, 2011, Phosphorylation of p53 modifies sensitivity to ionizing radiation, Anticancer Res, 31, 2255
  100. Ou, 2005, p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation, Mol Biol Cell, 16, 1684, 10.1091/mbc.E04-08-0689 · DOI · Paper page
  101. Park, 2012, Identification of Akt interaction protein PHF20/TZP that transcriptionally regulates p53, J Biol Chem, 287, 11151, 10.1074/jbc.M111.333922 · DOI
  102. Patel, 2013, Readout of epigenetic modifications, Annu Rev Biochem, 82, 81, 10.1146/annurev-biochem-072711-165700 · DOI · Paper page
  103. Perez, 2010, Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway, J Cell Physiol, 225, 394, 10.1002/jcp.22285 · DOI
  104. Pfeifer, 2011, Next-generation sequencing: emerging lessons on the origins of human cancer, Curr Opin Oncol, 23, 62, 10.1097/CCO.0b013e3283414d00 · DOI
  105. Pietenpol, 1994, Sequence-specific transcriptional activation is essential for growth suppression by p53, Proc Natl Acad Sci USA, 91, 1998, 10.1073/pnas.91.6.1998 · DOI · Paper page
  106. Pietsch, 2007, The tetramerization domain of p53 is required for efficient BAK oligomerization, Cancer Biol Ther, 6, 1576, 10.4161/cbt.6.10.4719 · DOI
  107. Puca, 2009, Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells, Oncogene, 29, 4378, 10.1038/onc.2010.183 · DOI
  108. Ray, 2012, The DNA binding and accumulation of p53 from breast cancer cell lines and the link with serine 15 phosphorylation, Cancer Biol Ther, 13, 848, 10.4161/cbt.20835 · DOI
  109. Resnick, 2003, Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity, Proc Natl Acad Sci USA, 100, 9934, 10.1073/pnas.1633803100 · DOI · Paper page
  110. Ribeiro, 2001, An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma, Proc Natl Acad Sci USA, 98, 9330, 10.1073/pnas.161479898 · DOI · Paper page
  111. Rinn, 2011, To repress or not to repress: This is the guardian's question, Trends Cell Biol, 21, 344, 10.1016/j.tcb.2011.04.002 · DOI
  112. Rodriguez, 2012, Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy, Cell Cycle, 11, 4436, 10.4161/cc.22778 · DOI
  113. Rokudai, 2013, MOZ increases p53 acetylation and premature senescence through its complex formation with PML, Proc Natl Acad Sci USA, 110, 3895, 10.1073/pnas.1300490110 · DOI
  114. Roy, 2010, Structural insight into p53 recognition by the 53BP1 tandem Tudor domain, J Mol Biol, 398, 489, 10.1016/j.jmb.2010.03.024 · DOI
  115. Sabapathy, 2012, Role of the JNK pathway in human diseases, Prog Mol Biol Transl Sci, 106, 145, 10.1016/B978-0-12-396456-4.00013-4 · DOI
  116. Saito, 2003, Phosphorylation site interdependence of human p53 post-translational modifications in response to stress, J Biol Chem, 278, 37536, 10.1074/jbc.M305135200 · DOI · Paper page
  117. Sakaguchi, 1997, Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53, Biochemistry, 36, 10117, 10.1021/bi970759w · DOI · Paper page
  118. Schumacher, 2010, Structure of the p53 C-terminus bound to 14-3-3: implications for stabilization of the p53 tetramer, FEBS Lett, 584, 1443, 10.1016/j.febslet.2010.02.065 · DOI
  119. Serrano, 2013, DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair, Oncogene, 32, 2452, 10.1038/onc.2012.257 · DOI
  120. Slee, 2010, Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo, Proc Natl Acad Sci USA, 107, 19479, 10.1073/pnas.1005165107 · DOI
  121. Sluss, 2010, Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis, Mol Cancer Res, 8, 216, 10.1158/1541-7786.MCR-09-0324 · DOI
  122. Song, 2007, p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM, Nat Cell Biol, 9, 573, 10.1038/ncb1571 · DOI · Paper page
  123. Stebbing, 2013, The regulatory roles of phosphatases in cancer, Oncogene
  124. Strebhardt, 2010, Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy, Nat Rev Drug Discov, 9, 643, 10.1038/nrd3184 · DOI · Paper page
  125. Sugikawa, 1999, Inhibition of mutant p53 phosphorylation at serine 15 or serine 315 partially restores the function of wild-type p53, Biochem Biophys Res Commun, 261, 256, 10.1006/bbrc.1999.1019 · DOI
  126. Tang, 2008, Acetylation is indispensable for p53 activation, Cell, 133, 612, 10.1016/j.cell.2008.03.025 · DOI · Paper page
  127. Terzian, 2008, The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss, Genes Dev, 22, 1337, 10.1101/gad.1662908 · DOI · Paper page
  128. Teufel, 2009, Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2, Oncogene, 28, 2112, 10.1038/onc.2009.71 · DOI · Paper page
  129. Theuerkorn, 2011, Prolyl cis/trans isomerase signalling pathways in cancer, Curr Opin Pharmacol, 11, 281, 10.1016/j.coph.2011.03.007 · DOI
  130. Timofeev, 2013, p53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo, Cell Rep, 3, 1512, 10.1016/j.celrep.2013.04.008 · DOI
  131. Trojer, 2007, L3MBTL1, a histone-methylation-dependent chromatin lock, Cell, 129, 915, 10.1016/j.cell.2007.03.048 · DOI · Paper page
  132. Ullrich, 1993, Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53, Proc Natl Acad Sci USA, 90, 5954, 10.1073/pnas.90.13.5954 · DOI
  133. Valente, 2013, p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa, Cell Rep, 3, 1339, 10.1016/j.celrep.2013.04.012 · DOI · Paper page
  134. Valenti, 2011, Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop, Cell Cycle, 10, 4330, 10.4161/cc.10.24.18682 · DOI
  135. Dieck, 2009, Posttranslational modifications affect the interaction of S100 proteins with tumor suppressor p53, J Mol Biol, 394, 922, 10.1016/j.jmb.2009.10.002 · DOI
  136. Vogelstein, 2013, Cancer genome landscapes, Science, 339, 1546, 10.1126/science.1235122 · DOI · Paper page
  137. Warnock, 2008, Influence of tetramerisation on site-specific post-translational modifications of p53: comparison of human and murine p53 tumor suppressor protein, Cancer Biol Ther, 7, 1481, 10.4161/cbt.7.9.6473 · DOI
  138. Warnock, 2011, Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53, Cancer Biol Ther, 12, 1059, 10.4161/cbt.12.12.18141 · DOI
  139. Waterman, 1998, ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins, Nat Genet, 19, 175, 10.1038/542 · DOI · Paper page
  140. West, 2011, Regulation of p53 function by lysine methylation, Epigenomics, 3, 361, 10.2217/epi.11.21 · DOI
  141. West, 2010, The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine 382 to target gene repression, J Biol Chem, 285, 37725, 10.1074/jbc.M110.139527 · DOI
  142. Wiech, 2012, Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2, PLoS One, 7, e51426, 10.1371/journal.pone.0051426 · DOI · Paper page
  143. Xu, 2012, Mechanistic links between ATM and histone methylation codes during DNA repair, Prog Mol Biol Transl Sci, 110, 263, 10.1016/B978-0-12-387665-2.00010-9 · DOI
  144. Yang, 2009, Plk1-mediated phosphorylation of Topors regulates p53 stability, J Biol Chem, 284, 18588, 10.1074/jbc.C109.001560 · DOI
  145. Yap, 2004, Ser392 phosphorylation regulates the oncogenic function of mutant p53, Cancer Res, 64, 4749, 10.1158/0008-5472.CAN-1305-2 · DOI
  146. You, 2012, Cancer genetics and epigenetics: two sides of the same coin, Cancer Cell, 22, 9, 10.1016/j.ccr.2012.06.008 · DOI · Paper page
  147. Zannini, 2012, DBC1 phosphorylation by ATM/ATR inhibits SIRT1 deacetylase in response to DNA damage, J Mol Cell Biol, 4, 294, 10.1093/jmcb/mjs035 · DOI
  148. Zerbini, 2005, Blockage of NF-κB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells, Cell Cycle, 4, 1247, 10.4161/cc.4.9.1966 · DOI
  149. Zhu, 2012, Wip1-dependent signaling pathways in health and diseases, Prog Mol Biol Transl Sci, 106, 307, 10.1016/B978-0-12-396456-4.00001-8 · DOI
  150. Zilfou, 2009, Tumor suppressive functions of p53, Cold Spring Harb Perspect Biol, 1, a001883, 10.1101/cshperspect.a001883 · DOI · Paper page

Cited by

See all 69

Metadata

Authors
Nguyen, T.-A., Menendez, D., Resnick, M. A., & Anderson, C. W.
Venue
Human Mutation
Publisher
Wiley
Published
2014-02-11
Volume
35
Issue
6
Pages
738-755
ISSN
1059-7794
DOI
10.1002/humu.22506
Cited by
69
References
29
Language
en
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 567 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mutant TP53 Posttranslational Modifications: Challenges and Opportunities. https://app.cochat.ai/papers/10.1002/humu.22506
The paper
Nguyen, T.-A., Menendez, D., Resnick, M. A., & Anderson, C. W. (2014). Mutant TP53 Posttranslational Modifications: Challenges and Opportunities. Human Mutation. https://doi.org/10.1002/humu.22506

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.